As of 2015, Director of R&D at Syntacoll GmbH, Saal a.d. Donau, Germany and Innocoll Biotherapeutics, Princeton, NJ, U.S.A. (Collagen API Matrices, Cellular and Molecular Mechanisms of Immune Pathogenesis of COVID-19) From 2009–2015, Head of R&D at Virologik GmbH, Erlangen, Germany (Proteasome Inhibitors for Treatment of Viral Infections (HIV, HCV, Influenza A) From 2008-2009, Chief Scientific Officer at Meridian Biopharmaceuticals GmbH, Vienna, Austria (Immune Therapy of Cancer, Therapeutic Glycosylation-Optimized Monoclonal Antibodies) From 2006–2009, Chief Scientific Officer at VelaLabs, Vienna, Austria (Protein Analytics) From 2002–2006, Head of R&D at Igeneon GmbH, Vienna, Austria (Therapeutic Antibodies and Multi-Epitope Cancer Vaccines) From 1994–2001, Project leader at Boehringer Ingelheim, Vienna, Austria (Gene Therapy, Non-viral Vectors and Cellular Cancer Vaccine) From 1991–1994, Post Doc, Teikyo University, Tokyo, Japan (Cytokines and Complement System) 1989, M.D. PhD from Humboldt University, Berlin, Germany (Biological Activity of Mutants of TNF alpha)